Reported research findings
- No established human clinical trials define effective dosing, meaningful fat loss, or safety in people to date.
WEIGHT & METABOLIC RESEARCH
5-Amino-1MQ
A small-molecule NNMT inhibitor studied in models for fat metabolism and NAD+ preservation.
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), researched for its role in metabolic optimization. Evidence to date is preclinical—demonstrated in cell and animal models—showing effects on fat metabolism and NAD+ preservation without impacting food intake. Human efficacy and safety data remain limited.
Why BLP features 5-Amino-1MQ
Included as an emerging research compound with a specific, well-defined enzyme target (NNMT) and compelling preclinical data. Human efficacy and safety data remain limited, so it is presented as experimental despite growing research interest.
Mechanism
Inhibits the NNMT enzyme, preventing wasteful methylation of nicotinamide and preserving NAD+ levels.
Increases intracellular NAD+ and SAM, modeled as boosting mitochondrial efficiency and fat oxidation.
In adipocyte models, reduces lipogenesis and promotes smaller fat-cell size and white-to-brown fat shifts.
WHAT THE RESEARCH MEASURED
Research findings
Findings describe study outcomes, not expected personal results.
Preclinical findings
- In obese animal models: significant reductions in body weight, white adipose tissue mass, and adipocyte size.
- Reported improved insulin sensitivity and lower plasma cholesterol, with enhanced fat burning and no appetite change.
- Reported boosted energy production and mitochondrial function in models.
- Reported very mild tolerability signals; injectable form associated with minimal reported side effects in research use.
Regulatory status
5-Amino-1MQ is investigational with primarily preclinical evidence and no established human efficacy or safety trials. Sold and offered strictly for laboratory and research use.